CP
DFTX

Castleview Partners’s Definium Therapeutics DFTX Stock Holding History

Castleview Partners’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16
Closed -$115 – 770
2024
Q2 		$115 Hold
16
– – ﹤0.01% 896
2024
Q1 		$150 Hold
16
– – ﹤0.01% 874
2023
Q4 		$59 Buy
+16
New +$48 ﹤0.01% 851

Other funds holding DFTX

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Castleview Partners's DFTX Position: Q3 2024 in Review

Castleview Partners sold out of Definium Therapeutics (DFTX) in Q3 2024, closing a stake of 16 shares — an estimated $115 sold.

Castleview Partners first reported a position in DFTX in Q4 2023 and held it in 3 quarters. The position peaked at $150 in Q1 2024. 157 funds tracked by Wall St. Rank hold DFTX as of Q3 2024.

  • Castleview Partners reported no remaining Definium Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Castleview Partners sold 16 Definium Therapeutics shares in Q3 2024, an estimated $115.
  • Castleview Partners first reported a position in Definium Therapeutics in Q4 2023 and held it in 3 quarters.
  • Castleview Partners's Definium Therapeutics position peaked at $150 in Q1 2024.
  • 157 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2024.

Based on Castleview Partners's 13F filing for Q3 2024, filed 9 Oct 2024.